Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Scholar Rock Holding Corp is a biotechnology business based in the US. Scholar Rock Holding shares (SRRK) are listed on the NASDAQ and all prices are listed in US Dollars. Scholar Rock Holding employs 145 staff and has a trailing 12-month revenue of around $42.7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $7.09 |
|---|---|
| 52-week range | $4.33 - $36.43 |
| 50-day moving average | $8.50 |
| 200-day moving average | $11.71 |
| Wall St. target price | $26.71 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.03 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.09 from 2022-10-03
| 1 week (2022-09-27) | 4.57% |
|---|---|
| 1 month (2022-09-02) | -21.31% |
| 3 months (2022-07-05) | 20.58% |
| 6 months (2022-04-05) | -47.83% |
| 1 year (2021-10-05) | -75.78% |
|---|---|
| 2 years (2020-10-05) | -54.41% |
| 3 years (2019-10-04) | 9.36 |
| 5 years (2017-10-01) | N/A |
| Revenue TTM | $42.7 million |
|---|---|
| Gross profit TTM | $18.8 million |
| Return on assets TTM | -20.25% |
| Return on equity TTM | -45.91% |
| Profit margin | -293.57% |
| Book value | $6.38 |
| Market capitalisation | $357.9 million |
TTM: trailing 12 months
We're not expecting Scholar Rock Holding to pay a dividend over the next 12 months.
Over the last 12 months, Scholar Rock Holding's shares have ranged in value from as little as $4.325 up to $36.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Scholar Rock Holding's is 0.5455. This would suggest that Scholar Rock Holding's shares are less volatile than average (for this exchange).
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.